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Summary Dialysis patients are more likely than the general population to develop
active tuberculosis (TB). In these patients, the availability of a highly sensitive and
speciﬁc test to diagnose latent TB will ensure earlier treatment and decreased pro-
gression to active disease. In the current study, the Quanti-FERON-TB Gold In-Tube(TST);
QTF-G test; (QFT-G) test was compared with the tuberculin skin test (TST) for the diagnosis of
latent tuberculosis infection (LTBI) among 200 hemodialysis patients and 15 con-Dialysis;
Hemodialysis;
Chronic renal failure;
ﬁrmed TB disease cases in a tertiary care center in Saudi Arabia. Among the LTBI
cases, 26 (13%) were TST positive, and 65 (32.5%) were positive by the QTF-G test,
with an overall agreement between the 2 tests of 75.5% (k = 0.34) being observed.
∗ Corresponding author at: King Saud Bin Abdulaziz University for Health Sciences, Head of Pulmonary Division, King Abdulaziz
Medical City, Riyadh, Saudi Arabia. Tel.: +966 12520088x17597/17531; fax: +966 505224271.
E-mail addresses: Jahdalih@gmail.com, jahdalih@ngha.med.sa (H. Al Jahdali).
1876-0341/$ — see front matter © 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.jiph.2013.02.002
Comparison of the tuberculin skin test and Quanti-FERON-TB Gold In-Tube (QFT-G) test 167
Among the conﬁrmed tuberculosis disease cases, none were positive by TST, and 10
(66.7%) were positive by the QTF-G test, resulting in an overall agreement of 33.3%
(k = 0). A comparison between the TST and the QTF-G test was performed based on the
sensitivity, speciﬁcity, and area under the curve (AUC) obtained for the tests. The QTF-
G test was more sensitive and less speciﬁc than the TST in predicting the conﬁrmed
TB disease cases. When we tested the correspondence of the AUC values between the
2 diagnostic modalities, the obtained p-value was 0.0003. In conclusion, the AUCs of
the examined diagnostic modalities are signiﬁcantly different in predicting LTBI and
tuberculosis.
Latent tuberculosis
infection
© 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
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tient hemodialysis unit of KAMC-R. We screened
all of the hemodialysis patients in our hemodial-
ysis unit for LTBI over a period of 5 months fromLtd. All rights reserved.
ntroduction
hen dialysis patients are infected by bacilli of
he Mycobacterium tuberculosis complex, they are
0—25 times more likely than immunocompetent
eople to develop active tuberculosis (TB) [1—5]. In
audi Arabia, the risk of active TB is estimated to
e approximately 50—92 times that in the general
opulation [6—9]. The higher TB incidence observed
n patients on dialysis is attributed to the lowered
ellular immunity caused by the state of chronic
enal failure [10]. Furthermore, the case fatality
ate of TB in dialysis patients appears to be higher
han that of TB in the general population, ranging
rom 17% to 75% [2,6,8—15]. This higher mortality
ate may largely be associated with late diagnosis
nd treatment [4], which, in turn, is due to the TB
ymptoms occasionally being confused with uremic
ymptoms and the fact that in dialysis patients, TB
ay present with nonspeciﬁc symptoms in approx-
mately 50% of cases [2,8].
The detection and treatment of latent tubercu-
osis infection (LTBI) in this population are crucial
o prevent the progression to active TB and the
econdary transmission of the infection to other
atients and health care workers (HCWs). There-
ore, a test for early detection of LTBI in these
atients is essential, and hence, current guide-
ines advocate screening hemodialysis patients for
TBI [1—3]. The tuberculin skin test (TST) has
ong been the standard method for detecting LTBI.
owever, this TST has 2 major disadvantages: a
igh percentage of dialysis patients show false
egative TST results, due to anergy, and false pos-
tive TST results, due to cross-reactivity with the
acille-Calmette-Guerin (BCG) immunization and
ontuberculous Mycobacterium (NTMB) infection
4—7]. The availability of M. tuberculosis (MTB)
ntigen-speciﬁc interferon-gamma (IFN-) release
ssays (IGRAs) represents a signiﬁcant advancement
n the diagnosis of LTBI.
A
b
p
aIGRAs are a newly developed type of blood test
hat measure the production of IFN-a by sensitized
ymphocytes after the blood is stimulated with the
peciﬁc TB antigens culture ﬁltrate protein 10 (CFP-
0) and early secretory antigen 6 (ESAT-6). These
ntigens are encoded in the RD-1 portion of the
TB genome. They are not found in BCG strains
r most NTMB and are therefore more speciﬁc [8].
wo IGRAs are commercially available: the Quanti-
ERON-TB Gold In-Tube (QFT-G) assay (Cellestis
td., Carnegie, Australia) and the T-SPOT.TB assay
Oxford Immunotec, Abingdon, UK). Limited data
re available on the usefulness of IGRAs in the
iagnosis of TB infection in hemodialysis patients.
ata from low-TB prevalence countries have indi-
ated that the IGRAs are better diagnostic tools
han the TST for LTBI [9—11,13]. Studies performed
n high-TB prevalence countries have also recently
ound that IGRA is a reasonable alternative to the
ST in hemodialysis patients [14,15]. The aim of
he present study was to compare the performance
f the QTF-G test and the TST for detecting LTBI
mong hemodialysis patients at King Abdulaziz Med-
cal City-National Guard Hospital-Riyadh (KAMC-R)
nd to investigate the agreement between these 2
ests in the detection of tuberculosis infection in a
opulation showing an intermediate TB prevalence
16].
ubjects and methods
he study participants were hemodialysis patients
ho were recruited prospectively from the outpa-ugust to December 2010. Patients who agreed to
e enrolled in the study were interviewed by our
ublic health nurse to explain the study’s purpose,
nd these patients all provided written informed
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consent. All patients who were diagnosed with
conﬁrmed TB disease were also recruited to par-
ticipate.
The following information was obtained: demo-
graphic data, underlying medical problems, contact
with the TB index case, history of LTBI or ther-
apy, and documentation of current or previous TB
treatments. Blood was drawn for the QTF-G test on
the same day that the patients were attached to
the dialysis machine. The TST was performed after
the initiation of dialysis on the same day and after
drawing blood for the QTF-G test.
Tuberculin skin test (tst)
The TST employed in this study was Tubersol —
Tuberculin Puriﬁed Protein Derivative (Mantoux), 5
TU per 0.1ml, test manufactured by Sanoﬁ Pasteur
Limited, Toronto, Ontario, Canada.
A trained and experienced public health nurse
performed all TSTs. Five tuberculin units (0.1ml) of
the puriﬁed protein derivative (PPD) were adminis-
tered via intradermal injection on the volar surface
of the forearm that did not have the arteriovenous
vessel. The responses were read within 72 h by the
same nurse, usually during the next regularly sched-
uled HD visit. An induration of 10mm or more in
transverse diameter was used as the threshold to
classify the test results as positive for LTBI. Patients
with an induration of less than 10mm upon initial
testing were considered to be negative and were
administered a second TST within 3—6 weeks to
elicit a potential booster response [2]. The results
obtained from the 2-step testing were used in all
further analyses. The TST was considered to be pos-
itive if either the 1st or 2nd test showed a response
of 10mm or more.
Quanti-FERON-TB Gold In-Tube (QFT-G) test
Blood was collected before the administration of
the TST, and the test was performed according
to the manufacturer’s instructions [17]. One ml of
whole blood was collected in each of 3 separate
test tubes: 1 containing no antigen (nil control), 1
with a mitogen (phytohemagglutinin, positive con-
trol) and 1 with TB antigens (ESAT-6, CFP-10 and
TB7.7). The 3 tubes were incubated overnight for
18—20 h at 37 ◦C. Following incubation, the tubes
were centrifuged, and the plasma was removed
from each tube and frozen at −20 ◦C. Measurement
of IFN- via ELISA was subsequently performed
in batch testing. The results were expressed in
IU/ml, as determined from a standard curve run
on each plate. According to the manufacturer’s
instructions, a value of 0.35 IU/ml or more for the
t
5
n
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elationship ([IFN- in the TB antigen tube]− [IFN-
n the negative control tube]) was considered to be
positive result. If the IFN- level was less than
.35 IU/ml in the TB antigen tube and the mito-
en control was positive (≥0.5 IU/ml), the test was
ecorded as negative.
adiological assessment
chest X-ray (CXR) was ordered if one had not
een performed within the previous 3 months. All
f the radiological reports were then reviewed, and
ll CXRs that were reported as abnormal were re-
xamined by an independent pulmonologist who
as blinded to the TST and QTF-G results.
The CXR results were divided into suggestive
f active tuberculosis, in which case the patient
as referred for further investigation, or consis-
ent with a previous TB infection, associated with
ndings such as upper lobe ﬁbronodular disease,
ranulomata, calciﬁed mediastinal lymph nodes
nd/or pleural thickening. Patients with 1 or more
dditional risk factors for tuberculosis in addi-
ion to hemodialysis, such as diabetic nephropathy,
revious kidney transplant, use of immunosuppress-
nts during the previous 3 months, a CXR showing
hanges consistent with untreated, but not active
B or a history of contact with active TB and a
MI < 20, were categorized as showing a high likeli-
ood for LTBI [2].
In this study, the gold standard references for
ST and QTF-G sensitivity and speciﬁcity were the
onﬁrmed TB disease cases, which showed either
ulmonary or extrapulmonary TB. Conﬁrmation was
ased on a positive culture for tuberculosis or
ranuloma in the biopsy and the response to anti-
uberculosis therapy.
tatistical analyses
ontinuous variables, such as age, were reported as
he mean± standard deviation (Mean± SD), while
ategorical variables, such as gender and TST, were
eported as numbers and percentages (n [%]). The
verall agreement between the QTF-G test and the
ST was evaluated using the kappa (K) coefﬁcient
nd concordance cases. The agreement between
he QTF-G test and the TST was stratiﬁed by the
onﬁrmed treated tuberculosis disease status. The
ssociation between the TB disease status and cat-
gorical variables, such as gender and the TST and
TF-G test results, was assessed using Chi-square
ests. If the expected frequency was smaller than
, then Fisher’s exact test was used as an alter-
ative to the Chi-square test. p-Values less than
.05 were considered to be signiﬁcant. Finally, to
Comparison of the tuberculin skin test and Quanti-FERON-TB Gold In-Tube (QFT-G) test 169
Table 1 Demographic and clinical characteristics of LTBI and TB disease.
Characteristics Level N (%)
Demographic, clinical characteristics and diagnostic modalities among 215 patients
Age (Mean± SD) 62.27± 11.79
Gender Female 112 (52.1)
Documented TB casesa Positive 15 (7.0)
Result of ﬁrst and second TST Positive 26 (12.1)
QTF-G test Positive 75 (34.9)
Demographic, clinical characteristics and diagnostic modalities among 200 patients screened for LTBI
(no TB disease)
Age (Mean± SD) 58.42± 17.65
Duration of dialysis (Mean± SD) 60.1± 175.2
Gender Female 103 (51.5)
BCG vaccine Yes 28 (14.0)
BCG scar Yes 29 (14.5)
TST 1st test Positive 22 (11.0)
Result of ﬁrst and second TST Positive 26 (13.0)
QTF-G test Positive 65 (32.5)
High likelihood of tuberculosis infectionb Positive 154 (77.0)
Diabetic nephropathy Yes 127 (63.5)
Kidney transplant Failed 21 (10.5)
Immunosuppressant in the last 12M Yes 2 (1.0)
Chest X-ray result Abnormal 10 (5.0)
History of contact with TB patients Yes 0 (0.0)
BMI ≤20 25 (12.5)
a Documented TB cases: deﬁned as patients with conﬁrmed diagnosis of tuberculosis disease based on positive tuberculosis
culture or biopsy showing granuloma and good response to anti-tuberculosis therapy.
b High likelihood of LTBI: deﬁned as contact with TB case, abnormal chest X-ray, DM, immunosuppressant in the last 12M, failed
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akidney transplant or BMI≤ 20.
valuate the 2 diagnostic modalities, traditional
easures of diagnostic accuracy were used, such
s the sensitivity, speciﬁcity, positive predictive
alue, negative predictive value and AUC. Further
nalyses explored the performance of the 2 diag-
ostic modalities when predicting the likelihood of
TBI. A high likelihood of LTBI was indicated if any
f the following were recorded: diabetic nephropa-
hy, failed kidney transplant, immunosuppressant
se in the last 12M, an abnormal chest X-ray result
onsistent with changes suggestive of old untreated
uberculosis, a history of contact with an open TB
ase and a BMI≤ 20. All statistical calculations were
erformed with SAS version 9.2.
esults
uring the study period, 200 patients were
ecruited to be tested for LTBI using both the TST
nd GTF-G test. During the study period, 15 patients
resented with a conﬁrmed diagnosis of TB dis-
ase. Among the 200 patients screened for LTBI,
27 (63.50%) exhibited diabetic nephropathy; 21
10.50%) failed kidney transplant; 2 (1%) had been
c
T
m
wiven immunosuppressants in the last 12 months;
0 (5%) displayed an abnormal CXR result consistent
ith inactive TB; no patient had a history of con-
act with a TB patient; 25 (12.50%) presented a low
MI (≤20); 154 (77%) exhibited a high likelihood risk
or LTBI; and 28 (14%) reported that they had been
iven a BCG vaccination in the past. Other demo-
raphic and clinical characteristics of the cases
ith LTBI are shown in (Table 1). The TST classi-
es a patient as being positive for LTBI if the result
f either the 1st TST or 2nd TST is ≥10mm. Of the
00 patients screened for LTBI, 26 (13%) were pos-
tive, and 174 (87%) were negative by the TST. The
TF-G test results showed that 65 (32.5%) of the
atients screened for LTBI were positive, and 135
67.5%) were negative. Thus, the percentage of LTBI
etected by the QTF-G test was substantially higher
han that by the TST (32.5% vs. 13%). Table 2 shows
he associations between the demographic and clin-
cal characteristics of the LTBI and TB disease cases
nd the TST and QTF-G results. The percentages of
oncordance and Kappa coefﬁcients between the
ST and the QTF-G test were 75.5% (fair agree-
ent,  = 0.34) in the 200 hemodialysis patients
ith LTBI and 33.3% (no agreement other than what
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Table 2 Associations between demographics and clinical characteristics and TB status.
Characteristics Level Tuberculosis status p-Value
Screened for LTBI
(no disease) (n = 200)
Conﬁrmed
tuberculosis disease
cases (n = 15)
Gender, n (%) Male 97 (48.5%) 6 (40.0%) 0.525
Female 103 (51.5%) 9 (60.0%)
Age (Mean± SD) 58.42± 17.65 62.27± 11.79 0.408
TST Negative 174 (87.0%) 15 (100.0%) 0.225
Positive 26 (13.0%) 0 (0.0%)
QTF-G test Negative 135 (67.5%) 5 (33.33%) 0.007
Positive 65 (32.5%) 10 (66.7%)
Table 3 Agreement between TST and QTF-G among LTBI and TB diseases cases.
QFT (+ve)* n (%) QFT (−ve)* n (%) Concordance 
Patients without TB n = 200
TST (+ve) n (%) 21 (10.5) 5 (2.5) 75.5% 34%
TST (−ve) n (%) 44 (22) 130 (65)
Patients with TB disease n = 15
TST (+ve) n (%) 0 (0.0) 0 (0.0) 33.3% 0%
TST (−ve) n (%) 10 (66.7) 5 (33.3)
a
f
g
w
a
w
s+ve = positive; −ve = negative.
would be expected by chance,  = 0.0) in the 15
hemodialysis patients with conﬁrmed TB disease
(Table 3). Table 4 shows that the TST was negative
in all of the conﬁrmed TB disease cases (sensitiv-
ity = 0.0%). In contrast, the QTF-G test displayed a
speciﬁcity of 67.5% and a sensitivity of 66.7%. When
we tested the correspondence of the AUC between
the 2 diagnostic modalities, the obtained p-value
was signiﬁcant (p = 0.0003), and a difference was
found between the AUC of the TST (AUC= 0.435)
o
i
t
Table 4 The performance of the GTF-G test and TST amon
Accuracy GTF-G test
Predicting tuberculosis disease (TB)
Sensitivity [95% CI] 0.667 [0.428
Speciﬁcity [95% CI] 0.675 [0.610
PPV [95% CI] 0.133 [0.056
NPV [95% CI] 0.964 [0.934
AUC [95% CI] 0.671[0.528—
Predicting of high likelihood of LTBI
Sensitivity [95% CI] 0.331 [0.257
Speciﬁcity [95% CI] 0.696 [0.563
PPV [95% CI] 0.785 [0.685
NPV [95% CI] 0.237 [0.165
AUC [95% CI] 0.512 [0.437nd that of the QTF-G test (AUC = 0.671). The TST
ailed to identify cases with conﬁrmed TB disease,
iving a positive predictive value (PPV) of 0.0%,
hile the QTF-G test had a PPV of 13.3%. The neg-
tive predictive value (NPV) of the TST was 92.1%,
hile the QTF-G test NPV was 96.4% (Table 4). The
ensitivity of detecting a high risk for the likelihood
f tuberculosis infection of the 2 diagnostic modal-
ties was low for both tests, at 33.1% for the QTF-G
est and 12.3% for the TST (Table 4).
g TB disease and high likelihood of LTBI.*.
TST
—0.905] 0.000 [0.000—0.000]
—0.740] 0.870 [0.823—0.917]
—0.210] 0.000 [0.000—0.000]
—0.995] 0.921 [0.882—0.959]
0.814] 0.435 [0.300—0.570]
—0.406] 0.123 [0.071—0.175]
—0.829] 0.848 [0.744—0.952]
—0.885] 0.731 [0.560—0.901]
—0.309] 0.224 [0.162—0.286]
—0.590] 0.486 [0.427—0.544]
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iscussion
uberculosis remains a serious global health
roblem, especially among immunocompromised
atients, such as those receiving hemodialysis. The
arly diagnosis and treatment of LTBI in dialysis
atients is very challenging, especially in a pop-
lation that has received the BCG vaccine. False
ositive TST results may be caused by a previous
CG vaccination or by infection with an atypical
ycobacterium. Therefore, more reliable tests are
equired for detecting LTBI in dialysis patients, par-
icularly as they are at high risk of progression to
B. The QTF-G test has been shown to improve
iagnostic accuracy for LTBI. However, limited data
re available on how the TST and QTF-G compare
mong dialysis patients in both LTBI and active TB
isease.
In this study, we found that LTBI in the hemodial-
sis patients was detected by the TST and QTF-G
est in 26 (13%) and 65 (32.5%) patients, respec-
ively. The 13% positivity observed for the TST in our
atients is lower than the rates reported recently
rom 6 countries, which ranged from 19% to 40%
10,13—15,18—20]. The low rate of positive TST
esults found in our population could be due to
he presence of a small number of patients with
B disease, excluding TB cases for whom there is
o information about TST and QTF-G results, and is
ost likely due to associated co-morbidities, such
s the number of diabetic and immunosuppressed
atients, which was much higher in our study than
n studies from Korea and Taiwan [14,15]. Further-
ore, other researchers have shown that the QTF-G
est is more likely than the TST to provide positive
esults in cases of TB disease [8,18,21]. The overall
iscriminatory ability between individuals with and
ithout TB disease was not satisfactory, as the sen-
itivities of the 2 diagnostic modalities were low,
t 33.1% for the QTF-G test and only 12.3% for the
ST.
In this study, the 2 tests (QTF-G test and TST)
ere compared and evaluated based on their
ensitivity, speciﬁcity, positive predictive value,
egative predictive value and AUC. The AUC was
.671 for the QTF-G test and 0.435 for the TST
n detecting TB disease, whereas the AUC values
btained for LTBI cases were 0.512 for the QTF-
and 0.486 for the TST. These results indicate
hat these tests exhibit different accuracies in diag-
osed tuberculosis disease and LTBI and that the
iscriminatory ability of the QTF-G test is superior
o that of the TST. The major strength of our study
s its reasonably large number of participants. How-
ver, one limitation the study presents is that we
nly considered a size of 10mm as the cutoff forN-TB Gold In-Tube (QFT-G) test 171
ndicating positive TST, and we did not correlate
alues less than 10mm to the QTF-G test. This cor-
elation is expected to be crucial, as some of our
ST-negative patients and QTF-G-positive patients
ith conﬁrmed TB may require a different cutoff
oint for predicting positivity. Additionally, all of
he results that were lower than the positive cutoff
alue for the QTF-G test were reported as negative.
inary diagnostic tests were considered here; our
uture research will focus on tests with continuous
easures.
In conclusion, screening all dialysis patients
sing the QTF-G test instead of the TST may be a
easonable method to ensure the early diagnosis of
TBI and, hence, to initiate proper early therapy.
n addition, a need exists to explore new diagnostic
ools for LTBI and TB disease with better discrimi-
atory power.
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